Annamaria Catino - Concepedia

Author

Annamaria Catino

Also Known As

A CATINO, A Catino, A. Catino, A. M. Catino, A.M. Catino, AM CATINO, ANNAMARIA CATINO, Anna Catino, Anna Maria Catino, Annamaria Catino

237

Publications

Citations

H-Index

Concepts

All Affiliations

Istituto Tumori Bari Istituti di Ricovero e Cura a Carattere Scientifico Fondazione IRCCS Istituto Nazionale dei Tumori University of Parma Ospedale Policlinico San Martino

About

Annamaria Catino is an author at Istituto Tumori Bari specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	1.2K
2	Health Sciences	2	2	87
3	Engineering	1	1	19
4	Public Health	1	1	77
5	Biomedical Engineering	1	1	14

Annamaria Catino

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study M. De Lena, Vito Lorusso, Agnese Latorre, European Journal of Cancer Advanced Ovarian CancerMedicinePharmacologyGynecologyPhase Ii Study	2001	167
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer Caroline A. Nebhan, Alessio Cortellini, Weijie Ma, JAMA Oncology	2021	146
Radiofrequency Ablation of 40 Lung Neoplasms: Preliminary Results Cosmo Damiano Gadaleta, Vittorio Mattioli, Giuseppe Colucci, American Journal of Roentgenology	2004	106
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, Journal for ImmunoTherapy of Cancer	2020	95
Myocardial Atrophy and Chronic Mechanical Unloading of the Failing Human Heart Nikolaos Diakos, Craig H. Selzman, Frank B. Sachse, Journal of the American College of Cardiology MechanobiologyCardiomyopathyHeart FailureStructural Heart DiseaseCardiovascular Disease	2014	89
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna, Cancer Immunology Immunotherapy Advanced NsclcOncologyFirst-line Pembrolizumab EffectivenessPd-l1 ExpressionImmune Checkpoint Inhibitor	2020	87
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Clinical Lung Cancer Pd-l1 ExpressionClinical EpidemiologyImmunologyImmune Checkpoint InhibitorClinical Outcomes	2020	82
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy Arsela Prelaj, Sara Elena Rebuzzi, Pamela Pizzutilo, Clinical Lung Cancer Prognostic EvaluationPrognostic BiomarkersOncologyMedicineImmunology	2020	80
VEGF concentration from plasma‐activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model Rosa Patruno, Nicola Arpaia, Cosmo Damiano Gadaleta, Journal of Cellular and Molecular Medicine	2008	79
Breath Analysis: Comparison among Methodological Approaches for Breath Sampling Alessia Di Gilio, Jolanda Palmisani, Gianrocco Ventrella, Molecules	2020	78

Page 1